At the end of the course participants will be able to:
– have a deeper knowledge of diagnostic modalities for thoracic malignancies
– be familiar with the most up to date form of treatment according to stage
– be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages
– be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).
Check the Symposium timetable for your time zone here https://time.is/en/compare
November 5, 2021
The times indicated are CET – Central European Time (UTC + 1)
08:15
08:4508:45
09:00Greetings from Scientific Director and Authorities Federico Raveglia
MODULE I
HOW TO APPROACH IIIA STAGE NON SMALL CELL LUNG CANCER –
Part I
CHAIRS: Alessandro Brunelli – David Jones
09:00
09:20Subgroups of Stage IIIA lung cancer: Does it matter?
Gaetano Rocco
09:20
09:40Mediastinal staging: When and with which method?
Hasan Fevzi Batirel
09:40
10:00Surgery versus Curative Chemoradiation: What does the evidence show?
Anthony Thomas D’Amico
10:00
10:20Immunotherapy combined with chemo/radiotherapy in resectable non-small cell lung cancer: impact on surgical outcomes and clinical endpoints
Diego Cortinovis
10:20
10:40How to approach locoregional failure after neoadjuvant or curative treatment?
Stefano Arcangeli
10:40
11:00Questions and discussion on the above topics
Alessandro Brunelli, David Jones
11:00
11:30Break
MODULE II
HOW TO APPROACH IIIA STAGE NON-SMALL CELL LUNG CANCER
PART II
CHAIRS: Anthony Thomas D’Amico, Marco Scarci
11:30
11:50Could robotic surgery boost lung resection role in IIIA stage patients?
Giulia Veronesi
11:50
12:10Update on ongoing trials
Pierre Emmanuel Falcoz
12:10
12:30Salvage surgery in IIIA
David Jones
12:30
12:50Surgery for IIIA in elderly patients
Alessandro Brunelli
12:50
13:10Different subgroups, different approach? T3N1M0 - T1-3N2M0 - T4N0M0
Alessandro Brunelli, Pierre Emmauel Falcoz, David Jones, Giulia Veronesi
13:10
13:30Questions and discussion on the above topics
Anthony Thomas D’Amico, Marco Scarci
13:30
14:30Lunch
MODULE III
THYMOMA AND THYMIC CARCINOMA
CHAIRS: Giuseppe Cardillo, Gaetano Rocco
14:30
14:50Update on stage and classification
Maninder Kalkat
14:50
15:10The role of imaging in histology, stage and prognosis determination in patients referred to surgery for thymoma
Nuria Maria Novoa
15:10
15:30Prognostic factors for surgically treated thymoma and thymic carcinoma
Kostas Papagiannopoulos
15:30
15:50Surgery for recurrent thymoma or thymic carcinoma
Pier Giorgio Solli
15:50
16:00Questions and discussion on the above topics
Giuseppe Cardillo, Gaetano Rocco
16:00
16:30Break
MODULE IV
REAL LIFE EXPERIENCES
CHAIR: Marco Scarci
16:30
16:50Stage IIIA (induction therapy)
Federico Raveglia
16:50
17:10IIIA (surgery upfront)
Lorenzo Rosso
17:10
17:30IIIA (salvage surgery)
Cecilia Pompili
17:30
17:50Surgery for recurrent thymoma
Davide Patrini
17:50
18:00VIDEO SESSION. Surgical challenges in uniportal video assisted thoracic surgery. An overview from IIIA lung cancer to thymic malignancy
Diego Gonzalez Rivas
November 6, 2021
The times indicated are CET – Central European Time (UTC + 1)
08:00
08:30Start of the connection to the WEBINAR and opening
MODULE V
OPTIMIZE RESOURCES AND DELIVER EXCELLENT PATIENT CARE IN THORACIC SURGERY
CHAIRS: Isabel Schmitt-Opitz, Giulia Veronesi
08:30
08:50How to reduce mistakes in thoracic surgery
Marco Scarci
08:50
09:10Improve wait time performance in diagnostic assessment for Lung Cancer and patient experience of care
David Gerard Healy
09:10
09:30The role of minimal invasive surgery in a continuing process improvement programme for thoracic surgery
René Horsleben Petersen
09:30
09:50Lean lobectomy. Efficiency improvement in the operating room
Federico Raveglia
09:50
10:10Excellence also passes from surgeons’ optimal physical, mental and emotional life
Sridhar Rathiman
10:10
10:30Fit for surgery, where do we draw the line?
Luke Howard
10:30
11:00Break
MODULE VI
MALIGNANT PLEURAL MESOTHELIOMA: an update on diagnosis and treatment options
CHAIRS: Giuseppe Cardillo, Piergiorgio Solli
11:00
11:25The role of surgery in the individualized treatment era for malignant mesothelioma
Isabelle Schmitt-Opitz
11:25
11:50The role of radiotherapy after malignant pleural mesothelioma surgery
Stefano Arcangeli
11:50
12:15The management of malignant pleural mesothelioma: state of the art
Giuseppe Cardillo
12:15
12:40Questions and discussion
Giuseppe Cardillo, Piergiorgio Solli
12:40
13:00Closing remarks and greetings
Federico Raveglia
MODULE II – ADVANCED DISEASE
III° SESSION
CHAIR: Diego Cortinovis, Christian Rolfo
16:30
16:40Treatment of (un)resactable stage III lung cancer
Federico Cappuzzo
16:40
16:50Oligometastatic disease: when is too much for surgery?
Gaetano Rocco
16:50
17:00Multimodality approach for orphan diseases: MPM and SCLC
Jordi Remon
17:00
17:30Q&A
17:30
Closing of the webinar
Check the Symposium timetable for your time zone here https://time.is/en/compare
5/6 NOVEMBRE 2021 – VIRTUAL EDITION
The multidisciplinary treatment of lung cancer
INFO
International Thoracic Oncology Symposium | Email: info@thoraciconcology.it
ENDORSED BY
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by International Thoracic Oncology Symposium and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
© 2020 International Thoracic Oncology Symposium 2021 – Dev by IronMarketing